NEW YORK (GenomeWeb News) – Paris-based Cellectis today said that it has licensed to Harvard Bioscience division Harvard Apparatus exclusive, worldwide rights to manufacture and sell electroporation-based instruments owned by the firm.
Specifically, Harvard Apparatus will have rights to sell the instruments acquired by Cellectis from Cyto Pulse Sciences three months ago for $2.2 million. Among the assets acquired by Cellectis was technology for use with Cellectis' meganuclease platform.
Under terms of the alliance announced today, Harvard Apparatus will pay Cellectis $1.3 million. Cellectis said that it will retain some annual licensing fees owed by existing and new customers. In addition, Cellectis said that it retains all rights to the use of the products for its own research and development programs as well as in clinical trials and prophylactic or therapeutic procedures, for both humans and animals.
The instruments covered by the deal are the DermaVax, OncoVet, Hybrimune, Cyto-LVT-S, and Cyto-LVT-P.
"This license significantly expands the cell biology research product line offered by Harvard Apparatus under the Warner Instruments and BTX brands," Harvard Bioscience CEO Chane Graziano said in a statement. "The technology is quite unique and patent protected and will provide our research customers with new tools to perform their electroporation and electrofusion experiments."